Discover
CRDF
Cardiff Oncology, Inc.
1.29
2 x 0.92
2 x 1.62
bid
ask
-
0.01
0.77%
2 @ 05:29 AM
1.26 -0.03 (1.98%)
| Ytd | -54.09% | |
| 1y | -63.25% |
1.26
day range
1.30
1.16
52 week range
4.56
| Open | 1.28 | Prev Close | 1.30 | Low | 1.26 | High | 1.30 | Mkt Cap | 88.20M |
| Vol | 564.19K | Avg Vol | 1.21M | EPS | -0.67 | P/E | N/A | Forward P/E | -4.03 |
| Beta | 1.93 | Short Ratio | 8.06 | Inst. Own | 27.66% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-06 | 50-d Avg | 1.57 | 200-d Avg | 1.99 | 1yr Est | 10.75 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2024-11-07 | 2024-09 | -0.27 | -0.25 | 0.02 | 7.41% |
| 2024-08-08 | 2024-06 | -0.25 | -0.26 | -0.01 | -4.00% |
| 2024-05-02 | 2024-03 | -0.25 | -0.22 | 0.03 | 12.00% |
| 2024-02-29 | 2023-12 | -0.26 | -0.21 | 0.05 | 19.23% |
| 2023-11-02 | 2023-09 | -0.29 | -0.22 | 0.07 | 24.14% |
| 2023-08-09 | 2023-06 | -0.27 | -0.25 | 0.02 | 7.41% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2024-12-13 | Piper Sandler | Upgrade | Overweight | Overweight |
| 2024-11-08 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-09-06 | Craig-Hallum | Upgrade | Buy | |
| 2024-05-06 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-03-06 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-03-01 | Piper Sandler | Upgrade | Overweight | Overweight |
Profile
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2020-01-01 | ERLANDER MARK | Officer | 6.38K | Conversion of Exercise of derivative security |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Blackrock Inc. | 2.74M | 11.13M | 5.35% |
| 2024-09-29 | Vanguard Group Inc | 2.17M | 8.84M | 4.25% |
| 2024-09-29 | Geode Capital Management, LLC | 928.23K | 3.78M | 1.82% |
| 2024-09-29 | State Street Corporation | 832.65K | 3.39M | 1.63% |
| 2024-09-29 | MAI Capital Management | 663.36K | 2.70M | 1.30% |
| 2024-09-29 | Renaissance Technologies, LLC | 602.38K | 2.45M | 1.18% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Vanguard Total Stock Market Index Fund | 1.25M | 5.11M | 2.45% |
| 2024-10-30 | iShares Russell 2000 ETF | 956.64K | 3.89M | 1.87% |
| 2024-09-29 | Vanguard Extended Market Index Fund | 600.17K | 2.44M | 1.17% |
| 2024-08-30 | Fidelity Small Cap Index Fund | 404.51K | 1.65M | 0.79% |
| 2024-09-29 | College Retirement Equities Fund-Stock Account | 284.65K | 1.16M | 0.56% |
| 2024-10-30 | Fidelity Extended Market Index Fund | 244.67K | 995.80K | 0.48% |
Split
| Split | Date |
|---|---|
| 1 : 6 | 2019-02-20 |
| 1 : 12 | 2018-06-04 |
| 1 : 6 | 2012-05-30 |
| 111 : 1 | 2004-07-27 |